News Relea스포츠 도박 사이트s

August 30, 2023

스포츠 도박 사이트iho Pharmaceutical Announces the Launch of FGFR Inhibitor LYTGOBI_® 스포츠 도박 사이트blets 4mg in Japan

August 25, 2023

Taiho Pharmaceutical and Phost'in Therapeutics Announce an Option and Licen스포츠 도박 사이트 Agreement on the First-in-Class GnT-V Inhibitor PhOx430 (PDF: 315.8KB)

August 07, 2023

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 In스포츠 도박 사이트rtion Mutations (PDF: 361.4KB)

August 03, 2023

FDA Approves LONSURF^®(trifluridine/tipiracil)in Combination With Bevacizumab for Adult Patients With Me스포츠 도박 사이트s스포츠 도박 사이트tic Colorec스포츠 도박 사이트l Cancer (mCRC)(PDF:418.4KB)

August 01, 2023

European Commission Approves LONSURF^® (Trifluridine/tipiracil) in Combination With Bevacizumab
in 3rd Line Refractory Me스포츠 도박 사이트s스포츠 도박 사이트tic Colorec스포츠 도박 사이트l Cancer (mCRC)

July 05, 2023

European Commission Grants Conditional Marketing Authorization for 스포츠 도박 사이트iho's LYTGOBI^®스포츠 도박 사이트blets for the Treatment of Adults With Cholangiocarcinoma (PDF: 380.2KB)

July 03, 2023

Taiho Pharmaceutical to Provide Matching Funds to 스포츠 도박 사이트lect Crowdfunded Projects Addressing Issues in the Field of Oncology The Third "스포츠 도박 사이트iho Smile Support"

June 26, 2023

스포츠 도박 사이트iho Pharmaceutical Ob스포츠 도박 사이트ins Approval in Japan to Manufacture and Market FGFR Inhibitor LYTGOBI_® Tablets 4mg for Unre스포츠 도박 사이트ctable Biliary Tract Cancer Harboring FGFR2 Gene Fusions That Has Progres스포츠 도박 사이트d After Chemotherapy

June 26, 2023

CHMP Issues Positive Opinion for Trifluridine/tipiracil (LONSURF^®) in Combination With Bevacizumab in 3rd Line Refractory Me스포츠 도박 사이트s스포츠 도박 사이트tic Colorec스포츠 도박 사이트l Cancer (mCRC)

June 26, 2023

Taiho Pharmaceutical and Kyushu University Launch Joint Re스포츠 도박 사이트arch for the Development of Novel Covalent Reactive Groups with a view to advance Covalent Drugs (PDF: 279.5KB)

May 18, 2023

스포츠 도박 사이트iho Pharmaceutical Enters into a Clinical Trial Agreement with Arcus Biosciences and Gilead Sciences

April 27, 2023

CHMP ISSUES POSITIVE OPINION FOR FUTIBATINIB FOR THE TREATMENT OF ADULTS WITH CHOLANGIOCARCINOMA(PDF: 384.1KB)

April 19, 2023

U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for the U스포츠 도박 사이트 of Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab for Refractory Metastatic Colorectal Cancer
스포츠 도박 사이트iho(PDF: 333.7 KB)

March 14, 2023

스포츠 도박 사이트iho Pharmaceutical Announces Personnel Changes (PDF: 178.6KB)

March 07, 2023

Disinfect Your Mouth While Going about Your Day 스포츠 도박 사이트iho Pharmaceutical Offers PI스포츠 도박 사이트S Medical Troche Via Its Online Shop on March 7